In 2025, Russians purchased 11.93 million packages of medicinal products, dietary supplements, and cosmeceuticals for treating throat diseases based on lysozyme. The annual volume consumption of such products remained virtually unchanged year-on-year (-0.03%). The total sales volume of these products on the retail market last year exceeded RUB 4.33 billion (at retail prices, including VAT), with a ruble growth rate of 5.3% compared to 2024. From 2022 to 2024, physical demand for lysozyme-containing products had been declining, along with negative ruble dynamics, so the 2025 figures can be considered somewhat positive in this context.

Over 81.5% of the total volume and approximately 88.4% of the monetary value of lysozyme product sales are accounted for by medicinal products. However, the share of medicinal products has been steadily decreasing each year. Notably, the cost of a medicinal product containing lysozyme exceeds the average price of a dietary supplement package with a similar composition by about 70%. While Russians paid around RUB 229 per package of a lysozyme-containing dietary supplement last year, a package of the medication cost approximately RUB 400. Despite the comparatively small sales volume of dietary supplements in the analyzed group, their total number exceeds that of medicinal products by several times.

According to the databases "Retail Audit of Drug Sales in Russia (Total Sell-Out)" and "Retail Audit of Dietary Supplement Sales in Russia (Total Sell-Out)" from the analytical company RNC Pharma, the total assortment of lysozyme-containing products of all types in the retail market segment (including the online channel) in 2025 included 39 brands, representing 27 corporations. Sales of over 70 SKUs were recorded during the year. Over the past few years, about 10 new brands have entered the market, all of which fall into the dietary supplement category.

For a long time, the Russian market featured two throat preparations containing lysozyme: the brand Lizobakt from Bosnalek and Hexalise from Recordati. Even after the introduction of generics, these brands maintain dominant positions in the category. In 2025, Lizobakt accounted for over 65.8% of the volume and 72.8% of the monetary value among all lysozyme-containing products. However, despite its absolute leadership, the brand's share has noticeably declined over the past three years. In 2022, Lizobakt constituted 77.4% of all ruble sales in the category. Furthermore, while the brand showed a decline in monetary sales for its tablet form, Lizobakt Complete (a throat spray) demonstrated double-digit sales growth. In 2025, total Russian spending on the brand increased by 5%, while physical demand remained virtually unchanged (+0.7% in packages).

Second place is held by Recordati's Hexalise, although this brand significantly lags behind the leader in terms of sales value, accounting for 4.61% of all monetary sales in the category in 2025. Rising to third place, despite its relatively recent market entry, is the domestic drug Laringobakt from Binnopharm, with a share of 3.46%. Compared to 2024, ruble spending on it increased by 53%, and physical consumption grew by 28% over the year. Dropping to fourth place is the brand Laripront from Hexalo; last year, the drug accounted for 3.33% of the monetary sales volume in the group — a 28% decrease in ruble sales compared to 2024.

Interestingly, four of the products represented in the TOP-10 are dietary supplements. The most popular among them are Loranebol from Artelar and Lizoprim manufactured by Kvadrat-S, in seventh and eighth place, respectively. Among the leading brands, a new entry, "Bud Zdorov! Lysozyme Complex," can also be highlighted. This is a private label product of the Rigla pharmacy chain, also manufactured by Kvadrat-S. The product was introduced in 2024 and moved directly into 10th place in the ranking within a year.

Table. TOP-10 brand names of products for treating throat diseases with lysozyme, including drugs, dietary supplements, and cosmeceuticals, by monetary sales volume on the Russian retail pharmaceutical market in 2025

*including Lizobakt Complete spray